RU2015120365A - Ингибирующие олигонуклеотиды и их применение - Google Patents
Ингибирующие олигонуклеотиды и их применение Download PDFInfo
- Publication number
- RU2015120365A RU2015120365A RU2015120365A RU2015120365A RU2015120365A RU 2015120365 A RU2015120365 A RU 2015120365A RU 2015120365 A RU2015120365 A RU 2015120365A RU 2015120365 A RU2015120365 A RU 2015120365A RU 2015120365 A RU2015120365 A RU 2015120365A
- Authority
- RU
- Russia
- Prior art keywords
- oligonucleotide
- immune
- seq
- medicament
- produce
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims 31
- 230000002401 inhibitory effect Effects 0.000 title claims 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000001404 mediated effect Effects 0.000 claims 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 18
- 208000035475 disorder Diseases 0.000 claims 16
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 208000007882 Gastritis Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 3
- 230000035939 shock Effects 0.000 claims 3
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 2
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 230000000770 proinflammatory effect Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 239000003970 toll like receptor agonist Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/085547 WO2014082254A1 (en) | 2012-11-29 | 2012-11-29 | Inhibitory oligonucleotide and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018105485A Division RU2018105485A (ru) | 2012-11-29 | 2018-02-14 | Ингибирующие олигонуклеотиды и их применение |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015120365A true RU2015120365A (ru) | 2017-01-10 |
Family
ID=50827048
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015120365A RU2015120365A (ru) | 2012-11-29 | 2012-11-29 | Ингибирующие олигонуклеотиды и их применение |
| RU2018105485A RU2018105485A (ru) | 2012-11-29 | 2018-02-14 | Ингибирующие олигонуклеотиды и их применение |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018105485A RU2018105485A (ru) | 2012-11-29 | 2018-02-14 | Ингибирующие олигонуклеотиды и их применение |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9688992B2 (enExample) |
| JP (1) | JP6106280B2 (enExample) |
| KR (1) | KR102027023B1 (enExample) |
| AU (1) | AU2012395641B2 (enExample) |
| CA (1) | CA2891906A1 (enExample) |
| MX (1) | MX369618B (enExample) |
| PH (1) | PH12015501182B1 (enExample) |
| RU (2) | RU2015120365A (enExample) |
| SG (1) | SG11201504142WA (enExample) |
| WO (1) | WO2014082254A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014082254A1 (en) | 2012-11-29 | 2014-06-05 | Changchun Huapu Biotechnology Co., Ltd | Inhibitory oligonucleotide and use thereof |
| CN108431228A (zh) * | 2015-12-25 | 2018-08-21 | Sbi生物技术有限公司 | Tlr抑制性寡核苷酸及其用途 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| EP3468605A4 (en) * | 2016-06-08 | 2020-01-08 | President and Fellows of Harvard College | MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS |
| JP7145853B2 (ja) * | 2016-11-09 | 2022-10-03 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 適応免疫調節のための方法および組成物 |
| AU2018364542A1 (en) | 2017-11-08 | 2020-04-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
| CN112798796B (zh) * | 2021-01-04 | 2024-02-02 | 东南大学 | 一种基于dna-paint的细胞膜上pd-l1蛋白检测方法及序列 |
| WO2022170396A1 (en) * | 2021-02-12 | 2022-08-18 | ViraLok Therapeutics Pty Ltd | Agents and methods for therapy and prophylaxis |
| CN116370494A (zh) * | 2022-11-14 | 2023-07-04 | 南昌大学 | CpG寡核苷酸对糖尿病神经病理痛疾病药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072290A2 (en) | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
| CN102851295B (zh) | 2006-08-28 | 2015-01-07 | 长春华普生物技术有限公司 | Toll 样受体调节性寡核苷酸及其用途 |
| US8030289B2 (en) | 2008-08-06 | 2011-10-04 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotide and use thereof |
| CN101643496B (zh) | 2008-08-07 | 2015-09-09 | 长春华普生物技术有限公司 | 一种具有免疫抑制功能的寡核苷酸 |
| CA2762206C (en) | 2009-06-01 | 2017-06-27 | Idera Pharmaceuticals, Inc. | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9 |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| WO2014082254A1 (en) | 2012-11-29 | 2014-06-05 | Changchun Huapu Biotechnology Co., Ltd | Inhibitory oligonucleotide and use thereof |
-
2012
- 2012-11-29 WO PCT/CN2012/085547 patent/WO2014082254A1/en not_active Ceased
- 2012-11-29 US US14/442,799 patent/US9688992B2/en active Active
- 2012-11-29 RU RU2015120365A patent/RU2015120365A/ru not_active Application Discontinuation
- 2012-11-29 JP JP2015544288A patent/JP6106280B2/ja active Active
- 2012-11-29 SG SG11201504142WA patent/SG11201504142WA/en unknown
- 2012-11-29 AU AU2012395641A patent/AU2012395641B2/en not_active Ceased
- 2012-11-29 CA CA2891906A patent/CA2891906A1/en not_active Abandoned
- 2012-11-29 KR KR1020157014060A patent/KR102027023B1/ko not_active Expired - Fee Related
- 2012-11-29 MX MX2015006703A patent/MX369618B/es active IP Right Grant
-
2015
- 2015-05-27 PH PH12015501182A patent/PH12015501182B1/en unknown
-
2017
- 2017-05-25 US US15/605,488 patent/US10190122B2/en active Active
-
2018
- 2018-02-14 RU RU2018105485A patent/RU2018105485A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201504142WA (en) | 2015-06-29 |
| JP6106280B2 (ja) | 2017-03-29 |
| AU2012395641B2 (en) | 2019-10-03 |
| US20150299710A1 (en) | 2015-10-22 |
| RU2018105485A (ru) | 2019-08-14 |
| JP2015536659A (ja) | 2015-12-24 |
| PH12015501182A1 (en) | 2015-08-17 |
| MX369618B (es) | 2019-11-14 |
| AU2012395641A1 (en) | 2015-05-28 |
| US9688992B2 (en) | 2017-06-27 |
| RU2018105485A3 (enExample) | 2019-08-14 |
| CA2891906A1 (en) | 2014-06-05 |
| MX2015006703A (es) | 2015-08-05 |
| PH12015501182B1 (en) | 2018-10-03 |
| US10190122B2 (en) | 2019-01-29 |
| KR20150089019A (ko) | 2015-08-04 |
| US20170335325A1 (en) | 2017-11-23 |
| KR102027023B1 (ko) | 2019-09-30 |
| WO2014082254A1 (en) | 2014-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3344772B1 (en) | Antagonistic pdl1 aptamers and their applications in cancer therapy | |
| US20170175121A1 (en) | Self assembling nucleic acid nanostructures | |
| JP6680760B2 (ja) | アンタゴニストｉｃ ｐｄ−１アプタマー及びその癌治療関連用途への応用 | |
| JP2016522817A5 (enExample) | ||
| ES2743600T3 (es) | Métodos de tratamiento de los trastornos inflamatorios vasculares | |
| CN107922947A (zh) | 用于治疗肌萎缩性侧索硬化症(als)的mir‑155抑制剂 | |
| US9809823B2 (en) | DNA aptamers for promoting remyelination | |
| KR102027023B1 (ko) | 저해성 올리고뉴클레오티드 및 그의 용도 | |
| WO2015196146A2 (en) | Rna-based compositions and adjuvants for prophylactic and therapeutic treatment | |
| WO2012014945A1 (ja) | アジュバント活性を有する新規核酸およびその利用 | |
| EP3923944A1 (en) | Spt5 inhibitors and uses thereof | |
| JP2018534361A5 (enExample) | ||
| JP7066669B2 (ja) | 炎症性関節疾患の治療方法 | |
| CN101240271A (zh) | Toll样受体调节性寡核苷酸及其用途 | |
| TW201201817A (en) | Aptamer against NGF and use thereof | |
| CN105779458B (zh) | 对非小细胞肺癌具有抑制作用的核糖核酸适配体及包含其的药物组合物 | |
| JP6702938B2 (ja) | アンタゴニストｉｃ ｃｔｌａ−４アプタマー及びその免疫活性増強への応用 | |
| WO2023063242A1 (ja) | ＩＦＮ－γへ選択的に結合するオリゴヌクレオチドを含有する自己免疫性疾患治療薬およびそのオリゴヌクレオチド | |
| WO2013088853A1 (ja) | オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター | |
| US20170348393A1 (en) | Treatment of cns inflammatory disorders | |
| CN106103719A (zh) | 针对fgf2的适体及其应用 | |
| CN115137742A (zh) | 一种用于治疗肥胖症的rna递送系统 | |
| CN117679433A (zh) | 反义寡核苷酸在制备治疗胃癌药物中的应用 | |
| CN115137745A (zh) | 一种用于治疗胶质母细胞瘤的rna递送系统 | |
| US10584342B2 (en) | DNA aptamers specific to CD2000R1 and their therapeutic uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180404 |